title: Multicyclic dose-intensive chemotherapy supported by autologous blood progenitor cell transplantation for relapsed small cell lung cancer.
abstract: We report two cases with small cell lung cancer (SCLC) receiving multicyclic dose-intensified chemotherapy (DI-CT) supported by autologous blood progenitor cell transplantation (ABPCT). Both cases were initially treated with cisplatin (CDDP), etoposide (ETP) and concurrent thoracic irradiation, however they had recurrent disease within a year. After receiving conventional chemotherapy, they underwent multicyclic DI-CT consisting of CDDP, ETP and ifosfamide supported by G-CSF and ABPCT. Definite regression of the tumors was observed. Severe neutropenia and thrombocytopenia were encountered but they were reversible and no life-threatening complications were experienced. These results suggest the feasibility and effectiveness of multicyclic DI-CT and the usefulness of ABPCT as a treatment option for relapsed SCLC.
authors.affiliation: Department of Internal Medicine II, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
authors.forename: Nobukazu
authors.initials: N
authors.lastname: Fujimoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ueoka
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Kiura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tabata
authors.forename: Akihiro
authors.initials: A
authors.lastname: Bessho
authors.forename: Ichiro
authors.initials: I
authors.lastname: Takata
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Sunami
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Hiramatsu
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ikeda
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
authors.forename: Mine
authors.initials: M
authors.lastname: Harada
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide